Merck's Experimental Eye Treatment Remigromig Shows Vision Improvement in Late-Stage Trial, But Raises Safety Concerns

Merck & Co Inc announced positive results from a late-stage clinical trial of its experimental eye treatment, remigromig, for diabetes-related eye disease. The trial, involving 984 participants, showed that patients receiving remigromig gained an average of 9.1 to 8.7 letters on an eye chart, compared to 11.8 letters for the established drug ranibizumab. However, safety concerns were noted, with remigromig patients experiencing higher rates of proliferative diabetic retinopathy (6.7% and 6.1% vs. 0.9% for ranibizumab) and increased discontinuation due to side effects.